Silencing RNA (siRNA) is a powerful tool which can inhibit
the expression of select genes by binding to the respective counter-coded messenger
RNA and preventing its transcription. It is, however, limited by its
susceptibility to degradation by endogenous enzymes requiring a delivery system
to transport it to the cell. Researchers at University of Napoli, University of
Campania, University of Milano (Italy) used Purasorb (R) PLGA (Cat# CB001) available
from PolySciTech Division of Akina, Inc. (www.polyscitech.com)
as a distributed product from Corbion to develop a microfluidic system for
delivery of siRNA. This research holds promise to provide for improved
therapies in the future. Read more: Villano, Ersilia, Teresa Silvestri, Susy
Brusco, Erika Esposito, Chiara Infolfi, Thomas L. Moore, Emma Mitidieri et al.
"Emulsion-Solvent diffusion in a double-chip microfluidic platform for
scalable production of Lipid@ PLGA nanoparticles delivering siRNA
therapeutics." International Journal of Pharmaceutics (2025):
126440. https://www.sciencedirect.com/science/article/pii/S0378517325012773
“Abstract: Scalable nanoparticle manufacturing remains
a key bottleneck in the clinical translation of RNA-based nanomedicines. In
this study, we demonstrate the successful adaptation of a conventional
emulsion–solvent diffusion protocol into an automated microfluidic workflow,
illustrating its potential for streamlined and scalable nanoparticle
production. Using the Sunshine™ microfluidic platform (Unchained Labs), we
systematically optimized formulation and process parameters to produce
siRNA-loaded hybrid lipid–polymer nanoparticles, featuring a
poly(lactic-co-glycolic acid) (PLGA) core and a dipalmitoylphosphatidylcholine
shell (mDPPC@PLGA hNPs). Optimised mDPPC@PLGA hNPs exhibited key technological
features, matching or exceeding the quality of their benchtop equivalents
(bDPPC@PLGA hNPs). Using poly(vinyl alcohol) (PVA) as a stabilizer,
monodisperse mDPPC@PLGA hNPs with controlled size (<170 nm) and consistent
zeta potential (–30 mV) were achieved with production yields ≥ 40 %. The
ability of mDPPC@PLGA hNPs to effectively entrap and slowly release a siRNA
targeting nuclear factor NF-κB (siNFκB) was successfully demonstrated.
Structural characterization through thermodynamic and SAXS analyses confirmed
that the microfluidic produced hNPs retained comparable internal architecture
to their benchtop counterparts. Most notably, siNFκB-loaded mDPPC@PLGA hNPs
resulted in effective in vitro downregulation of NFκB in
lipopolysaccharide-stimulated A549 lung epithelial cells. Collectively, these
results establish a novel and robust approach for the scalable fabrication of
functional, siRNA-loaded hybrid nanoparticles via emulsion–solvent diffusion,
leveraging a commercially available, automated microfluidic system with a
serial chip configuration. Schematic representation of the adaptation of the
bench-top emulsion–solvent diffusion protocol to a microfluidic automated
nanoparticle synthesis system with a double-chip in series configuration for
the preparation of siRNA-loaded lipid@PLGA hNPs.”
PLGA (https://akinainc.com/polyscitech/products/polyvivo/index.php?highlight=CB001#h)
Benchtop to Bedside with MidWest GMP https://www.akinainc.com/midwestgmp/
Corbion Purasorb® Polymers: https://akinainc.com/polyscitech/products/purasorb/
Ashland-TM Polymer Products: https://akinainc.com/polyscitech/products/ashland/
BPR Akina's Free Scientific Conference (West
Lafayette, 4/29/26: (https://akinainc.com/bprconference/)
No comments:
Post a Comment